Alvotech (ALVO), a commercial-stage biotechnology company, on Thursday announced the closing of its previously declared, unwritten public offering of $26.07 million ordinary shares at an offering price of $3.75 per share on June 17, 2026.
In connection with the offering, the company has entered into subscription agreements with certain investors for a concurrent offering of $17.83 million ordinary shares at a price of $3.75 per share.
The gross proceeds from the concurrent offering are estimated to be approximately $67 million. The company expects to close the concurrent placement on or about June 25, 2026, subject to customary conditions.
The Alvotech Board has approved issuing $43.89 million shares to investors participating in the offering and concurrent private placement. Following its closure, the company expects its issued share capital to comprise approximately $39.04 million shares in total.
Total gross proceeds from the public offering and concurrent private placements are estimated to be approximately $165 million. Alvotech plans to use the proceeds to advance the development of its biosimilar assets, as well as funding its working capital and general corporate purposes.
BofA Securities, Jefferies and Evercore ISI acted as joint book-running managers for the offering.
Separately on June 15, 2026, the company had declared an underwritten public offering of its ordinary shares as well as a concurrent private placement for gross proceeds of approximately $125 million.
Alvotech is currently trading at $3.87, down 1.15%.
For more such biotech stock news, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.